Senior man looking at female nurse helping him to wear sweater in retirement home (Maskot/Getty Images)
Americans 60 and older can get a new RSV vaccine but should discuss it with their doctor first, U.S. health officials recommended Thursday.
The newly approved vaccines are expected to be ready in the fall, a time when flu shots and updated COVID-19 shots also will be available. Those eligible for the RSV vaccine should talk with their doctor to see if it is right for them, the Centers for Disease Control and Prevention said in a statement.
The CDC said adults with chronic heart or lung disease, weakened immune systems and those living in long-term care facilities are at higher risk for the respiratory infection.
RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms but it can be dangerous for infants and the elderly. A surge last year filled hospitals with wheezing children. There's no vaccine yet for kids, but one for pregnant women to prevent illness in infants may be coming too, pending approval from the Food and Drug Administration.
On Thursday, Dr. Rochelle Walensky, the outgoing CDC director, signed off on a recommendation made last week by an advisory panel of outside experts for a single dose of the vaccines made by Pfizer and GSK. The FDA approved the shots last month for adults 60 and older.
The CDC panel initially considered a stronger recommendation that everyone 65 and older get the shot. But they weakened their endorsement after several members had questions about how well it works in the feeblest of patients, whether boosters will be needed and be effective, and the cost.
Drugmaker GSK told the panel that its RSV vaccine would be between $200 and $295. Pfizer has not disclosed a price. The vaccines may hold up over multiple seasons and it’s not yet clear whether boosters will be recommended.
Others wanted a stronger endorsement for those 65 and older. Asking people to consult their doctor “is an absolute impediment" to getting more people vaccinated and an extra burden on health care providers, Robert Blancato, executive director of the National Association of Nutrition and Aging Services Programs, said Thursday.
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
Join Cheddar News as we break down the top headlines this morning including updates on the Jan. 6 hears, the PGA suspension of 17 of the world's best golfers, and NASA's plans to study UFOs.
Rick Pauls, President & CEO OF DiaMedica Therapeutics, joins Cheddar Innovates to discuss a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients.
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'
Catching you up on the stories you need to know this morning, mass shooting victims testify on Capitol Hill, the White House outlines its plan to vaccinate kids younger than five years old, and we break down how to protect yourself from monkeypox.
The pharmaceutical giant Moderna says its updated 'bivalent' booster shot provides a stronger immune response against the Omicron variant of COVID-19 specifically. This week, Moderna plans to submit preliminary data to U.S. health officials in the hopes that its new booster will be available later this summer. Dr. Sampson Davis, emergency medicine physician, joins Cheddar News to discuss.
NASA has announced that the first official full-color images will be beamed back to Earth from the James Webb Telescope on July 12. Gregory L. Robinson, the director of the James Webb Space Telescope Program in the NASA Science Mission Directorate, joined Cheddar News to discuss the anticipated image drop. “We expect to see the universe different," he said. "Webb will allow us to see much, much clearer and deeper into the universe."
On this episode of Cheddar Reveals, Professor Laurence Hurst, Director of The Milner Centre for Evolution, discusses the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up? Neville Sanjana, faculty member at NY Genome and New York University, breaks down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases; Cheddar gets a look at Curiosity Stream's 'The Butterfly Effect.'
Neville Sanjana, faculty member at NY Genome and New York University, joins Cheddar Reveals to break down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases.
